摘要
目的分析肝炎肝硬化合并2型糖尿病的治疗及临床预后。方法选取医院2015年1月-2018年5月收治的肝炎肝硬化合并2型糖尿病患者30例,合并轻度糖尿病患者给予饮食控制、适量运动;合并中重度糖尿病患者给予血糖监测、口服降糖药物及注射胰岛素治疗,所有患者均加用抗病毒、抗纤维化治疗,治疗48周。比较治疗前后的肝功能及血糖水平。结果治疗后ALB高于治疗前,ALT、TBIL及HBV-DNA载量均低于治疗前,差异均有统计学意义(P<0.05)。治疗后FPG、2 hPG均低于治疗前,差异均有统计学意义(P<0.05)。结论根据肝炎肝硬化合并2型糖尿病患者病情程度的不同采用合适的治疗方案,能有效改善患者预后。
Objective To analyze the treatment and clinical prognosis of hepatitis cirrhosis combined with type 2 diabetes.Methods 30 patients with hepatitis cirrhosis combined with type 2 diabetes from January 2015 to May 2018 in the hospital were selected,while mild diabetes patients were given dietary control and moderate exercise,and moderate and severe diabetes patients were given blood sugar monitoring,oral hypoglycemic drugs and insulin injection therapy.All patients were treated with antiviral and antifibrosis therapy.The total treatment cycle was 48 weeks.Compared the liver function and blood sugar status before and after treatment.Results After treatment,the ALB was higher than before treatment,ALT,TBIL and HBV-DNA load were lower than before treatment,the difference was statistically significant(P<0.05).After treatment,the FPG and 2 hPG were lower than before treatment,and the difference was statistically significant(P<0.05).Conclusion It can improve the prognosis of hepatitis cirrhosis patients with type 2 diabetes patients.
作者
孟桂霞
王立蓉
蔡莉静
MENG Guixia;WANG Lirong;CAI Lijing(Department of Phase/Clinical Trial Center,Nanjing Second Hospital,Nanjing University of Chinese Medicine,Jiangsu Province,Nanjing 210003,China)
出处
《临床合理用药杂志》
2019年第34期34-35,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
病毒性肝炎肝硬化
糖尿病
血糖
肝功能
Viral hepatitis cirrhosis
Diabetes
Blood sugar
Liver function
